How close are we to a success stratification tool for improving biological therapy in ulcerative colitis?

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi: 10.1016/S0140-6736(16)32126-2
   PubMed Web of Science ®Google Scholar
• Gajendran M, Loganathan P, Jimenez G, et al. A comprehensive review and update on ulcerative colitis. Disease-A-Month. 2019;65(12):100851. doi: 10.1016/j.disamonth.2019.02.004
   PubMed Web of Science ®Google Scholar
• Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606–1619. doi: 10.1016/S0140-6736(12)60150-0
   PubMed Web of Science ®Google Scholar
• Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018;16(3):343–356.e3. doi: 10.1016/j.cgh.2017.06.016
   PubMed Web of Science ®Google Scholar
• Leijonmarck C-E, Löfberg R, Öst Å, et al. Long-term results of ileorectal anastomosis in ulcerative colitis in Stockholm county. Dis Colon Rectum. 1990;33(3):195–200. doi: 10.1007/BF02134178
   PubMed Web of Science ®Google Scholar
• Solberg IC, Høivik ML, Cvancarova M, et al. Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study). Scand J Gastroenterol. 2015;50(12):1456–1462. doi: 10.3109/00365521.2015.1064991
   PubMed Web of Science ®Google Scholar
• Torres J, Caprioli F, Katsanos KH, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. ECCOJC. 2016;10(12):1385–1394. doi: 10.1093/ecco-jcc/jjw116
   Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in crohn’s disease: medical treatment. J Crohn’s & Colitis. 2020;14:4–22. doi: 10.1093/ecco-jcc/jjz180
   PubMed Web of Science ®Google Scholar
• Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohn’s & Colitis. 2022;16:2–17. doi: 10.1093/ecco-jcc/jjab178
   PubMed Web of Science ®Google Scholar
• Gros B, Kaplan GG. Ulcerative colitis in adults: a review. JAMA. 2023;330(10):951. doi: 10.1001/jama.2023.15389
   PubMed Web of Science ®Google Scholar
• Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45:1291–1302. doi: 10.1111/apt.14030
   PubMed Web of Science ®Google Scholar
• Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–1226. doi: 10.1056/NEJMoa1905725
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Panés J, D’Haens GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol. 2019;17(8):1541–1550. doi: 10.1016/j.cgh.2018.11.035
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374(18):1754–1762. doi: 10.1056/NEJMoa1513248
   PubMed Web of Science ®Google Scholar
• William S, Geert D, Doug W, et al. P025 Ozanimod efficacy, safety, and histology in patients with moderate-to-severe ulcerative colitis during induction in the phase 3 true north study. Am J Gastroenterol. 2020;115(1):S6–S7. doi: 10.14309/01.ajg.0000722896.32651.d6
   PubMedGoogle Scholar
• Marsal J, Barreiro-de Acosta M, Blumenstein I, et al. Management of non-response and loss of response to anti-tumor necrosis factor therapy in inflammatory bowel disease. Front Med. 2022;9:897936. doi: 10.3389/fmed.2022.897936
   Web of Science ®Google Scholar
• Chen C, Hartzema AG, Xiao H, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019;25(8):1417–1427. doi: 10.1093/ibd/izz001
   PubMed Web of Science ®Google Scholar
• Flamant M, Roblin X. Inflammatory bowel disease: towards a personalized medicine. Therap Adv Gastroenterol. 2018;11:1756283X1774502. doi: 10.1177/1756283X17745029
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137(4):1250–1260. doi: 10.1053/j.gastro.2009.06.061
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Jairath V, Jeyarajah J, et al. Development and validation of a clinical decision support tool that incorporates pharmacokinetic data to predict endoscopic healing in patients treated with infliximab. Clin Gastroenterol Hepatol. 2021;19(6):1209–1217.e2. doi: 10.1016/j.cgh.2020.04.078
   PubMed Web of Science ®Google Scholar
• Barré A, Colombel J-F, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47(7):896–905. doi: 10.1111/apt.14550
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Vande Casteele N, et al. Development and validation of clinical scoring tool to predict outcomes of treatment with vedolizumab in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(13):2952–2961.e8. doi: 10.1016/j.cgh.2020.02.010
   PubMed Web of Science ®Google Scholar
• Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol. 2002;37(7):818–824. doi: 10.1080/gas.37.7.818.824
   PubMed Web of Science ®Google Scholar
• Travis SPL, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 38(6):905–910.
   PubMed Web of Science ®Google Scholar
• Molander P, Af Björkesten C-G, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18(11):2011–2017. doi: 10.1002/ibd.22863
   PubMed Web of Science ®Google Scholar
• Dʼhaens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218–2224. doi: 10.1002/ibd.22917
   PubMed Web of Science ®Google Scholar
• Bromke MA, Neubauer K, Kempiński R, et al. Faecal calprotectin in assessment of mucosal healing in adults with inflammatory bowel disease: a meta-analysis. JCM. 2021;10(10):2203. doi: 10.3390/jcm10102203
   Google Scholar
• Stevens TW, Gecse K, Turner JR, et al. Diagnostic accuracy of fecal calprotectin concentration in evaluating therapeutic outcomes of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020:S1542356520311289.
   Web of Science ®Google Scholar
• Waljee AK, Liu B, Sauder K, et al. Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis. Aliment Pharmacol Ther. 2018;47(6):763–772. doi: 10.1111/apt.14510
   PubMed Web of Science ®Google Scholar
• Wetwittayakhlang P, Lontai L, Gonczi L, et al. Treatment targets in ulcerative colitis: is it time for all in, including histology? J Clin Med. 2021;10(23):5551. doi: 10.3390/jcm10235551
   PubMed Web of Science ®Google Scholar
• Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009;58(12):1612–1619. doi: 10.1136/gut.2009.178665
   PubMed Web of Science ®Google Scholar
• Verstockt B, Verstockt S, Dehairs J, et al. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. EBioMedicine. 2019;40:733–742. doi: 10.1016/j.ebiom.2019.01.027
   PubMed Web of Science ®Google Scholar
• Toedter G, Li K, Marano C, et al. Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis. Am J Gastroenterol. 2011;106(7):1272–1280. doi: 10.1038/ajg.2011.83
   PubMed Web of Science ®Google Scholar
• Smillie CS, Biton M, Ordovas-Montanes J, et al. Intra- and inter-cellular rewiring of the human colon during ulcerative colitis. Cell. 2019;178(3):714–730.e22. doi: 10.1016/j.cell.2019.06.029
   PubMed Web of Science ®Google Scholar
• Singh A, Fenton CG, Anderssen E, et al. Identifying predictive signalling networks for vedolizumab response in ulcerative colitis. Int J Colorectal Dis. 2022;37(6):1321–1333. doi: 10.1007/s00384-022-04176-w
   PubMed Web of Science ®Google Scholar
• Karmi N, Bangma A, Spekhorst LM, et al. Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFα therapy in inflammatory bowel disease. PLoS One. 2021;16(9):e0256860. doi: 10.1371/journal.pone.0256860
   PubMed Web of Science ®Google Scholar
• Voskuil MD, Bangma A, Weersma RK, et al. Predicting (side) effects for patients with inflammatory bowel disease: the promise of pharmacogenetics. WJG. 2019;25(21):2539–2548. doi: 10.3748/wjg.v25.i21.2539
   PubMed Web of Science ®Google Scholar
• Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with crohn’s disease. Gastroenterology. 2020;158(1):189–199. doi: 10.1053/j.gastro.2019.09.041
   PubMed Web of Science ®Google Scholar
• Corridoni D, Chapman T, Antanaviciute A, et al. Inflammatory bowel disease through the lens of single-cell RNA-seq technologies. Inflamm Bowel Dis. 2020;26(11):1658–1668. doi: 10.1093/ibd/izaa089
   PubMed Web of Science ®Google Scholar
• Tang F, Barbacioru C, Wang Y, et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods. 2009;6(5):377–382. doi: 10.1038/nmeth.1315
   PubMed Web of Science ®Google Scholar
• Martin JC, Chang C, Boschetti G, et al. Single-cell analysis of crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy. Cell. 2019;178(6):1493–1508.e20. doi: 10.1016/j.cell.2019.08.008
   PubMed Web of Science ®Google Scholar
• Agrawal M, Allin KH, Petralia F, et al. Multiomics to elucidate inflammatory bowel disease risk factors and pathways. Nat Rev Gastroenterol Hepatol. 2022;19(6):399–409. doi: 10.1038/s41575-022-00593-y
   PubMed Web of Science ®Google Scholar
• Ning L, Zhou Y-L, Sun H, et al. Microbiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts. Nat Commun. 2023;14(1):7135. doi: 10.1038/s41467-023-42788-0
   PubMed Web of Science ®Google Scholar
• Bastida G, Mínguez A, Nos P, et al. Immunoepigenetic regulation of inflammatory bowel disease: current insights into novel epigenetic modulations of the systemic immune response. Genes (Basel). 2023;14(3):554. doi: 10.3390/genes14030554
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338. doi: 10.1038/ajg.2015.233
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi: 10.1053/j.gastro.2020.12.031
   PubMed Web of Science ®Google Scholar
• Leung CM, Tang W, Kyaw M, et al. Endoscopic and histological mucosal healing in ulcerative colitis in the first year of diagnosis: results from a population-based inception cohort from six countries in asia. J Crohn’s & Colitis. 2017;11:1440–1448. doi: 10.1093/ecco-jcc/jjx103
   PubMed Web of Science ®Google Scholar
• Laharie D, Filippi J, Roblin X, et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther. 2013;37(10):998–1004. doi: 10.1111/apt.12289
   PubMed Web of Science ®Google Scholar
• Shah SC, Colombel J-F, Sands BE, et al. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(9):1245–1255.e8. doi: 10.1016/j.cgh.2016.01.015
   PubMed Web of Science ®Google Scholar
• Jangi S, Holmer AK, Dulai PS, et al. Risk of relapse in patients with ulcerative colitis with persistent endoscopic healing: a durable treatment endpoint. J Crohn’s & Colitis. 2021;15:567–574. doi: 10.1093/ecco-jcc/jjaa184
   PubMed Web of Science ®Google Scholar
• Yoon H, Jangi S, Dulai PS, et al. Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: a systematic review and meta-analysis. Gastroenterology. 2020;159(4):1262–1275.e7. doi: 10.1053/j.gastro.2020.06.043
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194–1201. doi: 10.1053/j.gastro.2011.06.054
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–787. doi: 10.1136/gut.2010.221127
   PubMed Web of Science ®Google Scholar
• Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–627.e3. doi: 10.1053/j.gastro.2014.05.008
   PubMed Web of Science ®Google Scholar
• Barreiro-de Acosta M, Vallejo N, de la Iglesia D, et al. Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): a longitudinal cohort study. ECCOJC. 2016;10:13–19. doi: 10.1093/ecco-jcc/jjv158
   Web of Science ®Google Scholar
• Jangi S, Yoon H, Dulai PS, et al. Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. Aliment Pharmacol Ther [Internet]. 2020 [cited 2021 Oct 16];52(6):1008–1016. Available from: https://onlinelibrary.wiley.com/doi/10.1111/apt.16026
   PubMed Web of Science ®Google Scholar
• Park S, Abdi T, Gentry M, et al. Histological disease activity as a predictor of clinical relapse among patients with ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2016;111(12):1692–1701. doi: 10.1038/ajg.2016.418
   PubMed Web of Science ®Google Scholar
• Bryant RV, Burger DC, Delo J, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65(3):408–414. doi: 10.1136/gutjnl-2015-309598
   PubMed Web of Science ®Google Scholar
• Pai RK, Hartman DJ, Rivers CR, et al. Complete resolution of mucosal neutrophils associates with improved long-term clinical outcomes of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(11):2510–2517.e5. doi: 10.1016/j.cgh.2019.12.011
   PubMed Web of Science ®Google Scholar
• Gui X, Bazarova A, Del Amor R, et al. PICaSSO histologic remission index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system. Gut. 2022;71(5):889–898. doi: 10.1136/gutjnl-2021-326376
   PubMed Web of Science ®Google Scholar
• Iacucci M, Parigi TL, Del Amor R, et al. Artificial intelligence enabled histological prediction of remission or activity and clinical outcomes in ulcerative colitis. Gastroenterology. 2023;164(7):1180–1188.e2. doi: 10.1053/j.gastro.2023.02.031
   PubMed Web of Science ®Google Scholar
• Sagami S, Kobayashi T, Miyatani Y, et al. Accuracy of ultrasound for evaluation of colorectal segments in patients with inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(5):908–921.e6. doi: 10.1016/j.cgh.2020.07.067
   PubMed Web of Science ®Google Scholar
• Smith RL, Taylor KM, Friedman AB, et al. Systematic review: clinical utility of gastrointestinal ultrasound in the diagnosis, assessment and management of patients with ulcerative colitis. J Crohns Colitis. 2020;14(4):465–479. doi: 10.1093/ecco-jcc/jjz163
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Katsurada T, Nishida M, et al. Usefulness of transabdominal ultrasonography for assessing ulcerative colitis: a prospective, multicenter study. J Gastroenterol. 2019;54(6):521–529. doi: 10.1007/s00535-018-01534-w
   PubMed Web of Science ®Google Scholar
• Sagami S, Kobayashi T, Aihara K, et al. Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. Aliment Pharmacol Ther. 2022;55(10):1320–1329. doi: 10.1111/apt.16817
   PubMed Web of Science ®Google Scholar
• Hindryckx P, Novak G, Bonovas S, et al. Infection risk with biologic therapy in patients with inflammatory bowel disease. Clin Pharma And Ther. 2017;102(4):633–641. doi: 10.1002/cpt.791
   PubMed Web of Science ®Google Scholar
• Imperatore N, Foggia M, Patturelli M, et al. Treatment-based risk stratification of infections in inflammatory bowel disease: a comparison between anti-tumor necrosis factor-α and nonbiological exposure in real-world setting. J Gastroenterol Hepatol. 2021;36(7):1859–1868. doi: 10.1111/jgh.15367
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400.e3. doi: 10.1053/j.gastro.2013.10.052
   PubMed Web of Science ®Google Scholar
• Wetwittayakhlang P, Tselekouni P, Al-Jabri R, et al. The optimal management of inflammatory bowel disease in patients with cancer. J Clin Med. 2023;12(6):2432. doi: 10.3390/jcm12062432
   PubMed Web of Science ®Google Scholar
• Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318(17):1679. doi: 10.1001/jama.2017.16071
   PubMed Web of Science ®Google Scholar
• Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161–170. doi: 10.1016/S2468-1253(21)00377-0
   PubMed Web of Science ®Google Scholar
• Cheng D, Kochar B, Cai T, et al. Comorbidity influences the comparative safety of biologic therapy in older adults with inflammatory bowel diseases. Am J Gastroenterol. 2022;117(11):1845–1850. doi: 10.14309/ajg.0000000000001907
   PubMed Web of Science ®Google Scholar
• Billiet T, Ferrante M, Van Assche G. The use of prognostic factors in inflammatory bowel diseases. Curr Gastroenterol Rep. 2014;16(11):416. doi: 10.1007/s11894-014-0416-y
   PubMedGoogle Scholar
• Noor NM, Lee JC, Bond S, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9:415–427. doi: 10.1016/S2468-1253(24)00034-7
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Novack L, Mao R, et al. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: a systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology. 2022;162(2):482–494. doi: 10.1053/j.gastro.2021.10.037
   PubMed Web of Science ®Google Scholar
• Vermeire S, Hanzel J, Löwenberg M, et al. Early versus late use of vedolizumab in ulcerative colitis: clinical, endoscopic, and histological outcomes. J Crohns Colitis. 2024;18(4):540–547. doi: 10.1093/ecco-jcc/jjad179
   PubMed Web of Science ®Google Scholar
• Wetwittayakhlang P, Gonczi L, Lakatos L, et al. Long-term Colectomy Rates of Ulcerative Colitis over 40 years of Different Therapeutic Eras–Results from a Western Hungarian Population-based Inception Cohort between 1977 and 2020. J Crohns Colitis. 2022;17(5):712–721. doi: 10.1093/ecco-jcc/jjac188
   Web of Science ®Google Scholar
• Singh S. Positioning therapies for the management of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023;20(7):411–412. doi: 10.1038/s41575-023-00744-9
   PubMed Web of Science ®Google Scholar
• Din S, Selinger CP, Black CJ, et al. Systematic review with network meta-analysis: risk of herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57(6):666–675. doi: 10.1111/apt.17379
   PubMed Web of Science ®Google Scholar